NCT05183230 WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
| NCT ID | NCT05183230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Suicide, Attempted |
| Study Type | INTERVENTIONAL |
| Enrollment | 115 participants |
| Start Date | 2022-04-22 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 115 participants in total. It began in 2022-04-22 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
Eligibility Criteria
Inclusion Criteria: * 50-90 years old * Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia * Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts." * We will also include patients on psychotropics and on after-care community psychotherapy. Exclusion Criteria: * Current diagnosis of Psychotic Disorders; Diagnosis of Dementia * Cognitive Impairment (MMSE ≤ 24) * Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry * Aphasia, sensory problems, and/or inability to speak English.
Contact & Investigator
Dimitris Kiosses, PhD
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT05183230 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Suicide, Attempted. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05183230 currently recruiting?
Yes, NCT05183230 is actively recruiting participants. Contact the research team at dkiosses@med.cornell.edu for enrollment information.
Where is the NCT05183230 trial being conducted?
This trial is being conducted at New York, United States, White Plains, United States.
Who is sponsoring the NCT05183230 clinical trial?
NCT05183230 is sponsored by Weill Medical College of Cornell University. The principal investigator is Dimitris Kiosses, PhD at Weill Medical College of Cornell University. The trial plans to enroll 115 participants.